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dritic cells are sufficient for initiating the rejection of mouse
islet allografts.
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Previously we have demonstrated that islets
ABSTRACT
of Langerhans treated with donor-specific anti-Ia serum and
complement survive when transplanted across the major histocompatibility complex of the mouse. In this study, using immunofluorescence, we demonstrate two morphologically distinct populations of Ia-positive cells scattered within the Ianegative islet tissue. A large irregularly shaped Ia-positive
subset of cells were identified as dendritic cells by using the
33D1 antibody specific for a mouse dendritic cell antigen. The
other small, round Ia-positive subset was 33D1 negative. Islets
pretreated with anti-dendritic cell antibody and complement
prior to transplantation survived in their histoincompatible recipients for >200 days. Rejection of stable islet allografts
promptly occurred when transplant recipients were challenged
with 1 x 105 donor dendritic cells 60 days after transplantation. These results demonstrate an important in vivo role for
donor dendritic cells in the stimulation of allograft rejection.

MATERIALS AND METHODS
Mice. B10.BR/SgSnJ (BlO.BR; H-2k) and C57BL/6J (B6;
H-2b) male mice (age, -5-6 weeks) were obtained from The
Jackson Laboratory.
B6 transplant recipients were made diabetic by the intravenous injection of streptozotocin (160 mg/kg of body
weight). Nonfasting plasma glucose levels were determined
three times a week on blood obtained from the orbital sinus
of B6 diabetic mice, and only mice with plasma glucose levels of >400 mg/dl for three consecutive bleedings were used
as recipients. Rejection was defined as a nonfasting serum
glucose of >250 mg/dl for two consecutive bleedings.
Islet Isolation. Islets were isolated by the collagenase technique as described (1). The isolated islets were separated on
a Ficoll gradient (Pharmacia) and hand picked with the aid of
a dissecting microscope (12).
Antibodies. The following antibodies were used for immunofluorescence assays: (i) A.TH anti-A.TL, a mouse alloantiserum that is directed against Ik determinants; (ii)
A.TL anti-A.TH, a mouse alloantiserum directed against P
determinants; (iii) 10-2.16, a mouse monoclonal antibody
that is directed against murine I-Ak (13); and (iv) 33D1, a rat
monoclonal antibody which is specific for mouse dendritic
cells (5, 10). The 33D1 antibody also was used for the treatment of allogeneic islets prior to transplantation. The A.TH
anti-A.TL and A.TL anti-A.TH antisera and the 10-2.16 reagent were produced in the Department of Genetics, Washington University School of Medicine. Cells for production
of 10-2.16 were obtained from the Salk Institute (San Diego,
CA). The monoclonal reagents were used in the form of culture supernatant.
Fluoresceinated goat anti-mouse IgG (Fl-anti-mouse IgG)
was purchased from Tago (Burlingame, CA) and used to localize A.TH anti-A.TL, A.TL anti-A.TH, and 10-2.16 antisera. Biotin-labeled mouse anti-rat immunoglobulin (B-antirat Ig) and fluorescein-avidin (Fl-avidin) (Vector Laboratories, Burlingame, CA) were used for staining with the 33D1
reagent (10).
Rabbit sera (GIBCO) were screened by the microcytotoxicity test (14) in order to select one that lacked toxicity to
islets while maintaining a high degree of specific complement activity.
Immunofluorescence. After isolation, islets either were
processed immediately or were maintained in tissue culture
medium (CMRL 1066) at 37°C in 95% air for 12 hr. The islets

Rejection of mouse islet allografts is prevented when donor
histoincompatible islets are treated with anti-Ia antiserum
and complement prior to transplantation (1). Because the islet cells are la- (2), the antiserum treatment presumably
eliminates Ia+ donor lymphoid cells. As proposed previously, these passenger lymphocytes may be the donor cells responsible for initiating islet graft rejection (1, 3).
Previous studies have suggested that the principal type of
passenger leukocyte is the dendritic cell (4-6). Dendritic
cells are bone marrow-derived (7) Ia' cells (8, 9) that express a specific antigen identified with a monoclonal antibody 33D1 (10) but lack the characteristic markers of other
leukocytes such as F4/80 and Mac-1 (macrophages), surface
Ig (B cells), and thy-1, Lyt-1,2 (T cells) (9-11). Dendritic
cells are active stimulators of lymphocyte responses in culture, particularly the primary mixed lymphocyte response,
where they are 100 times more potent than unfractionated
spleen cell suspensions (4, 5). Small numbers of rat lymph
dendritic cells can induce the rejection of rat kidney allografts (6). In all of these studies, dendritic cells have been
derived from lymphoid organs or lymph. Dendritic cells have
not been identified previously in graft tissue using a cell-specific antibody.
In this study, we demonstrate by immunofluorescence
that dendritic cells are present in freshly isolated mouse islets of Langerhans and that these cells can be eliminated
with a monoclonal antibody to dendritic cells and complement. Pretreatment of donor mouse islets with anti-dendritic
cell antibody plus complement prior to transplantation prevented rejection of mouse islets transplanted across a major
histocompatibility barrier. These findings indicate that den-

Abbreviations: B6, C57BL/6J; B1O.BR, B1O.BR/SgSnJ; Fl-antimouse IgG, fluoresceinated goat anti-mouse IgG; B-anti-rat Ig, biotin-labeled mouse anti-rat immunoglobulin; Fl-avidin, fluorescein-
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were placed in glass Kimble tubes (100-150 islets per tube)
and washed three times in Hanks' solution supplemented
with 0.02% sodium azide. The islets were then incubated 45
min at room temperature with a 1:20 dilution of A.TH antiA.TL, a 1:2 dilution of 33D1 culture supernatant, or with
Hanks' solution and then were washed three times and incubated with rabbit complement (1:3 dilution) in Hanks' solution at 370C for 30 min. The islets were treated for 15 min
with DNase (1:10 dilution, 200 ,ug per tube) at 370C and then
washed by centrifugation three times in order to remove
lysed cells. The islets were then treated with A.TH antiA.TL (1:20 dilution), 10-2.16 (1:2 dilution), 33D1 (1:2 dilution), or Hanks' solution for 45 min at room temperature.
After this second incubation, the islets were resuspended in
a 1:20 dilution of Fl-anti-mouse IgG or a 1:40 dilution of Banti-rat Ig (30 min at 40C). The islets were washed three
times and pelleted, and the islets treated with B-anti-rat Ig
were subsequently treated with a 1:5 dilution of Fl-avidin (30
min at 40C). The treated and washed islets were resuspended
in 20 ptl of Hanks' solution and examined with a Leitz Orthoplan fluorescence microscope equipped with an epi-illuminator. The islets were scored for the number of fluorescentlabeled cells with dendritic cell morphology and those cells
resembling small lymphocytes. Fifty to 75 islets were counted in each experiment, and the mean number of fluorescent
cells per islet was recorded. The treatment protocols were
repeated at least twice with islets from different isolations.
Similar numbers of Ia' cells were observed in islets tested
either immediately after isolation or after 12 hr of incubation
in tissue culture medium; thus, the data were pooled in Fig.
1.
Islet Transplantation. Freshly isolated B10.flR islets were
incubated with monoclonal anti-dendritic cell reagent for 45
min at room temperature in Hanks' balanced salt solution
containing 0.5% bovine serum albumin. The treated islets
were washed twice by centrifugation and incubated for 30
min at 370C with rabbit complement. Control islets were
transplanted immediately after isolation or were treated with
only rabbit complement. Each B6 (H-2b) diabetic recipient
received 550-880 treated or untreated B10.BR (H-2k) islets

RESULTS
Identification of Ia' Lymphoid and Dendritic Cells in Isolated Islets. Immunofluorescence studies using alloantiserum
recognizing murine Ta determinants revealed two morphologically distinct populations of Ia' cells within B10.BR
mouse islets (Fig. 1, group 1). One population was composed
of large cells with finger-like protrusions, spaced between
the la- islet cells (Fig. 2) that were similar to the dendritic
cells described in lymphoid organs (8-11, 16). These cells
were present within the parenchyma of the islets and were
rarely observed on the islet surface. A second Ia' population was composed of small, round cells with cytoplasmic
projections that resembled small lymphocytes. The number
of dendritic-like cells ranged from 0 to 5 cells per islet, and
the number of lymphoid cells ranged from 0 to 3 cells per
islet, with the larger islets having more Ia' cells than smaller
islets. The ratio of dendritic cells to lymphocytes remained
constant (3:1) even though the size of the islets varied.
A monoclonal anti-I-A antibody also detected both lymnphoid-like and dendritic-like populations of Ia' cells within
B10.BR islets (Fig. 1, group 2), although the intensity of
staining and the total number of Ia' cells per islet was decreased in comparison to that observed with the alloantiserum. This may reflect the lower density of determinants
recognized by a monoclonal reagent or the qualitative or
quantitative expression of Ta specificities on the lymphoid
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by embolizing the islets into the terminal sinusoids of the
liver by injection into the portal vein (15). We have demonstrated previously that islets transplanted as isografts via the
portal vein will rapidly reverse the diabetic state to normal
and maintain normoglycemia in the recipients for >300 days
(1).
Dendritic Cells for Induction of Rejection. Donor B10.BR
dendritic cells were prepared from spleen cell suspensions as
described (16). Sixty-five days after transplantation, normoglycemic B6 mice with stable B10.BR islet transplants
were given a single injection of 1 x 105 viable cells enriched
for dendritic cells in 0.5 ml of medium via the tail vein.
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FIG. 1. Treatment of islets with allo-anti-la (A.TH anti-A.TL), monoclonal anti-Ia (10-2.16),
agents in the presence or absence of complement.
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FIG. 2. Immunofluorescence appearance of a dendritic cell in a BlO.BR islet. The islet was treated with allo-anti-la serum and Fl-anti-mouse

IgG.
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cells in the islets. Control B10.BR islets treated with an antiIa alloantiserum to an irrelevant haplotype (Is) demonstrated
background staining only (Fig. 1, group 8).
Treatment of islets with A.TH anti-A.TL antiserum, complement, and DNase reduced the number of dendritic and
lymphocytic cells detected by immunofluorescence to background levels (Fig. 1, group 4).
A monoclonal antibody to mouse dendritic cells (33D1)
was used to determine whether the large Ia' cells with elongated processes in the islets were dendritic cells. It is known
that the number of determinants detected by 33D1 is very
small (about 14,000 antibody binding sites per cell) compared
to >200,000 anti-I-A binding sites (9, 10). Therefore, the
more sensitive biotin/avidin modification of indirect immunofluorescence was used with 33D1 reagent. This technique
produced readily detectable staining of large dendritic cells
(Fig. 1, group 3) but did not stain the round cells which resembled small lymphocytes. The average number of 33D1'
dendritic cells per islet (2.0) was less than the number of Ia'
cells with dendritic-like morphology (3.5). This difference
was attributed to less intense staining with 33D1 and not to a
population of Ia', 33D1- dendritic cells because treatment
of islets with 33D1 antibody and complement eliminated all
of the Ia+ dendritic cells (Fig. 1, group 5). As expected, removal of Ia' cells eliminated 33D1+ cells (Fig. 1, group 6).
The Ia' lymphocyte-like cells lacked 33D1 determinants
both by immunofluorescence (Fig. 1, group 3) and by antibody-mediated cytotoxicity (Fig. 1, group 5). These results
indicate that most of the large Ia' cells in islets are related to
the 33D1+ dendritic cells previously isolated from lymphoid
organs.
Effects of Anti-Dendritic Cell Antibody on Islet Allograft
Survival. The majority (83%) of B6 recipients receiving untreated B1O.BR islets rejected the islets by 12 days after
transplantation (Fig. 3, group 1). These results are comparable to our previous studies (1) and those of Morrow et al.
(17). The small number that failed to reject the allografts may
represent animals that received islets with insufficient numbers of passenger cells to induce rejection. Islet allografts
treated with rabbit complement alone prior to transplanta-

tion were also acutely rejected (Fig. 3, group 2).
Transplants of B10.BR islets treated with monoclonal antimouse dendritic cell reagent (33D1) and complement resulted in allograft survival in eight of the nine recipients for at
least 65 days after transplantation (Fig. 3, group 3). One islet
graft was rejected at 12 days. As shown in Fig. 4A, the recipients remained normoglycemic beyond 200 days.
Initiation of Rejection of Established Islet Allografts with
Donor Dendritic Cells. Previous studies have demonstrated
that the intravenous injection of donor lymphoid cells would
induce the acute rejection of established islet allografts in
rats (3) and mice (1). For example, at 100 days after transplantation, established mouse islet allografts are rejected by
two injections of 1 x 107 donor splenocytes.
We studied four mice with established allografts 65 days
after transplantation of islets pretreated with anti-dendritic
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FIG. 3. Survival of fresh allogeneic islets (B1O.BR) transplanted
into nonimmunosuppressed diabetic recipients (B6). Group 1 (o) re-

cipients were transplanted with fresh untreated islets (n = 6). Group
2 (e) recipients were transplanted with islets treated with rabbit
complement (n = 5). Group 3 (A) recipients were transplanted with
islets treated with anti-dendritic cell antibody (33D1) and rabbit
complement (n = 9).
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transplantation. (A) Group A: plasma glucose levels remained normal after an islet allograft transplant for >200 days. (B) Group B:
four stable islet allograft recipients received 1 x 10' c Jonor cells enriched for dendritic cells. Islet allograft rejection wa s promptly induced.

cell antiserum and complement. The mice wer e challenged
intravenously with 1 x 105 donor cells enriched for dendritic
cells. Hyperglycemia occurred acutely in all foi ur recipients
within 6 days (Fig. 4B), indicating that this low d lose of donor
dendritic cells was capable of initiating rejectio tn.
DISCUSSION
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Marked prolongation of allograft survival is ac,hieved by a
variety of procedures directed toward altering oir eliminating

donor passenger 'lymphocytes prior to tran: splantation.
These procedures have been applied successfull: y to islets of
Langerhans and include islet culture at low Itemperature
(240C) (18) or in the presence of 95% oxygen (19)) and elimination of Ia' cells from the islets by specific aintisera and
complement (1). Rejection of long-term estabAlished islet
transplants can be induced with donor lymphoid cells (1, 20,
21). However, cell-specific monoclonal antibodie .s have seen
little use in defining the contribution of passenEger lymphocytes in transplantation.
Morphological studies have demonstrated the presence of
Ia' cells within rat islets (22) and within canine islets (23).
The present immunofluorescence study demon strates two
structurally distinct populations of Ia' cells wit hin isolated
mouse islets. One population of Ia' cells posse; ssed fingerlike processes and reacted with the 33D1 anti-di endritic cell
antibody, whereas the other Ia' population was 33D1- and
resembled lymphocytes. Only the dendritic-like cells were
eliminated by the specific anti-dendritic cellI antibody,
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whereas anti-Ia antiserum and complement eliminated both
lymphoid and dendritic-like cells. It is likely that the 33D1+
cells within the islet cells are related to the Ia' cells described by Hart and Fabre in most nonlymphoid organs (22).
Dendritic cells in vitro express large quantities of I region
determinants and are potent stimulators of mixed lymphocyte reactions (4, 5, 9, 16). A similar situation must exist in
situ. Treatment of donor islets with anti-dendritic cell antibody and complement prior to transplantation prevented the
rejection of islet allografts in 89% of the histoincompatible
recipients for >65 days. Four transplant recipients were followed for >200 days, and all four animals remained normoglycemic. Successfully engrafted mice were challenged 65
days after transplantation with 1 x 105 donor cells enriched
for dendritic cells and rejection was acutely induced in all
four animals. The dose of enriched dendritic cells sufficient
to induce rejection (1 x 105 per mouse) is notable because
previous studies demonstrated that the rejection of established mouse islet allografts required >1 x 1 donor cells if
splenocytes were used 100 days after transplantation (1).
Therefore, results of the present study demonstrate the potency of the dendritic cell preparations in eliciting graft rejections.
These in vitro and in vivo findings indicate that dendritic
cells are a potentially important component of transplantation rejection reactions, and that the presence of dendritic
cells alone within islets may be sufficient for the initiation of
mouse islet allograft rejection.
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